Latest News about CYBN
Recent news which mentions CYBN
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
June 18, 2024
From Benzinga
From Benzinga
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
May 09, 2024
From Benzinga
From Benzinga
From InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
From Benzinga
From Benzinga
3 High-Potential Penny Stocks to Turn $1000 into $1 million
March 10, 2024
From InvestorPlace
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
February 16, 2024
From Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
From Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
From Benzinga
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
From Benzinga
From Benzinga
From Benzinga
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
January 09, 2024
From Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
From Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
From Benzinga
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
December 14, 2023
From InvestorPlace
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
From Benzinga
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
December 03, 2023
Tickers
CYBN
From Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
From Benzinga
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
November 23, 2023
From Benzinga
From Benzinga
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
November 15, 2023
Tickers
CYBN
From Benzinga
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
From Benzinga
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
November 10, 2023
Tickers
CYBN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.